Latest From AngioDynamics Inc.
UK-listed BTG PLC is on a route to a major future in interventional medicine, having built solid foundations in licensing and specialty pharma. CEO Louise Makin describes the deal- and decision-making rationale that has allowed a mid-cap player to set billion-dollar plus ambitions in interventional medicine, based on organic and M&A growth.
The US agency released two final guidance documents with tips on 510(k)s for electrosurgical devices targeting general tissue cutting, coagulation or sealing indications.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
- Diagnostic Equipment & Supplies
- Radiofrequency Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Renal System
- North America
- Parent & Subsidiaries
- AngioDynamics Inc.
- Senior Management
James Clemmer, Pres. & CEO
Michael Greiner, EVP, CFO
- Contact Info
Phone: (518) 795-1400
14 Plaza Dr.
Latham, NY 12110
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.